# A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

> **NCT04993768** · PHASE2 · COMPLETED · sponsor: **Transposon Therapeutics, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** TPN-101, 100 mg/day
- **DRUG:** TPN-101, 200 mg/day
- **DRUG:** TPN-101, 400 mg/day
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04993768
- **Lead sponsor:** Transposon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-12
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-03-24
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993768, "A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04993768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*